Answers are grounded in this paper and cite their sources.
Women who carry a germline mutation in the BRCA1 or BRCA2 (BRCA1/2) gene have a 50%–80% lifetime risk of developing breast cancer and a 10%–40% lifetime risk of developing ovarian cancer (1–4). These high-risk women are being offered various preventive measures, including surveillance, chemoprevention, and prophylactic surgery to reduce their risk of cancer. During a prophylactic bilateral mastectomy or a prophylactic bilateral salpingo-oophorectomy, healthy breast or ovarian tissue, respectively, is removed to prevent the development of a malignancy. However, these procedures do not completely eradicate cancer risk because, often, not all tissue at risk is taken away (5–9). Because of the invasive and irreversible nature of prophylactic surgery, knowledge of its efficacy and the extent of risk reduction are crucial for women considering the procedure. Several groups have investigated the efficacy of bilateral prophylactic surgery in women with a family history of breast and/or ovarian cancer or in known BRCA1/2 mutation carriers (Table 1). For BRCA1/2 mutation carriers, prophylactic bilateral mastectomy was associated with an 85%–100% risk reduction for breast cancer (10,11), and a prophylactic salpingo-oophorectomy was associated with an 85%–96% risk reduction for ovarian cancer and a 53%–68% risk reduction for breast cancer (12,13). There are, however, specific methodologic problems associated with research evaluating the efficacy of prophylactic surgery. For example, was ovarian cancer more prevalent in families of women who opted for a prophylactic oophorectomy than it was in families of the comparison group? Might cancer events be overselected because women elected BRCA mutation testing after their cancer diagnosis? Might cancer events be overselected because a woman’s cancer diagnosis was the reason for prophylactic surgery in one of her relatives, while both of them are included in the study? The aim of this commentary is to discuss various biases that may occur in studies that estimate the risk reduction after prophylactic surgery. These insights may help evaluate previous investigations and help plan future efficacy studies. Studies of the efficacy of prophylactic surgery often include relatives, either because the study is family-based or because the study is center-based, and some members of the same family are counseled at the same center. Bias may arise if familial relationships are ignored in the analyses because individual decisions regarding genetic testing and preventive measures are likely to be influenced by cancer events that occur in relatives. In a hypothetical family (Fig. 1), woman 8 decided to seek advice about her cancer risk because her mother (woman 4) and grandmother (woman 1) had breast cancer and her aunt (woman 3) had ovarian cancer. Because genetic testing was unavailable at the time, she was advised to undergo breast screening. She informed her sisters and they also started screening. As soon as genetic testing for BRCA1/2 mutations became available, woman 8 visited a clinical genetic center. Her mother (woman 4), being the only living relative who had been diagnosed with breast cancer, was asked for permission to test her DNA. She agreed, and because she was found to be a carrier of a BRCA1 germline mutation, woman 8 could be tested. Woman 8 was found not to be a carrier of the mutation. Her sisters did not wish to be tested but continued with breast screening. However, one of her sisters (woman 6), diagnosed with breast cancer some time later, decided to be tested after all and was found to be a carrier. Woman 7 was very upset by the events happening to that sister and began to consider prophylactic surgery. After woman 7 was found to be a carrier, she opted for a bilateral mastectomy. Woman 5 continued breast screening and was not interested in genetic testing. The scenario above highlights the potential dependency between cancer diagnosis within the family and individual decisions of relatives to undergo screening, DNA testing, and/or prophylactic surgery. If these events are assumed to be independent in studies that include several members of the same family, bias such as confounding by indication and familial-event bias (see below), may arise. Rebbeck et al. (14) mentioned that 59% of the women were related to at least one other study subject, and 32% were related to at least four other study subjects; Meijers-Heijboer et al. (11) reported that they included a maximum of four study subjects from the same family. Despite acknowledging the relationship among study participants, neither of these studies (11,14) considered dependency between events within a family. By selecting the appropriate time period for members of one family to be at risk, bias can be prevented. In addition, the validity of efficacy studies may be increased by careful selection of study subjects. When evaluating the efficacy of prophylactic surgery, the aim is to identify two groups of women who differ in the exposure of interest, namely prophylactic surgery, but who are, or in the analysis can be made, similar with regard to other factors associated with disease outcome (15,16). Ideally, this could be accomplished in a randomized clinical trial, but randomization for prophylactic surgery is clearly unethical. Thus, observational study designs such as cohort studies are commonly used, but they can introduce several forms of bias. Selection of an appropriate comparison (i.e., nonsurgery) group for a valid evaluation of the cancer risk reduction after prophylactic surgery is difficult because BRCA1/2 mutation status is associated with a wide range of penetrance estimates (17–19). In our hypothetical family (Fig. 1), it is likely that, if the sister of woman 7 had not been recently diagnosed with cancer, woman 7 may not have considered prophylactic surgery. Moreover, had her sister been diagnosed with ovarian cancer rather than breast cancer, woman 7 might have preferred a prophylactic salpingo-oophorectomy. Thus, more cancer in the family leads to more prophylactic surgery, and the type of the prevailing cancer in the family may affect the type of surgery. Consequently, women who choose prophylactic salpingo-oophorectomy may have an inherently greater risk of ovarian cancer than women who do not, possibly resulting from a specific BRCA1/2 mutation (20,21) or to as yet unknown modifying genes. A comparison of surgery and nonsurgery subjects from families with BRCA1/2 mutations and a different baseline risk of ovarian cancer could thus lead to an underestimation of risk reduction from prophylactic salpingo-oophorectomy. Such underestimation would result in a bias referred to as “confounding by indication.” In their report on breast cancer risk after prophylactic salpingo-oophorectomy, Rebbeck et al. (14) mentioned the possibility of confounding by indication. The authors indicated that analyses stratified by ovarian cancer history were not feasible because 80% of the families had at least one family member with ovarian cancer. However, if an ovarian cancer family history was more frequent in the surgery group than in the nonsurgery group, selection bias would have been likely, and a subset analysis limited to women with an ovarian cancer family history might have been more valid. To date, none of the efficacy studies on prophylactic surgery for breast and/or ovarian cancer have considered possible differences in penetrance between families of BRCA1/2 mutation carriers with and without prophylactic surgery. Because of the similar underlying genetic cancer risk among siblings, confounding by indication could be reduced by matching women who undergo prophylactic surgery with their sisters who do not. Sister matching was used by Hartmann et al. (22). Investigators should also consider the age difference between sisters and the influence of cancer occurrence in one sister on the other sisters’ decisions regarding prophylactic measures (see the “Biases Associated With Start of Follow-Up” section). An obvious requirement for sister matching would be that the nonsurgery sisters are also proven BRCA1/2 mutation carriers. Because awareness of BRCA1/2 mutation status may be rare among cancer-free sisters, an alternative approach to sister matching could be a comparison of BRCA1/2 mutation carriers with and without prophylactic surgery within groups of families with a clearly specified cancer history (i.e., with or without ovarian cancer) or specific BRCA1/2 mutations. When evaluating breast cancer risk reduction associated with prophylactic salpingo-oophorectomy among BRCA1/2 mutation carriers, the occurrence of ovarian cancer may reduce available person-years at risk, especially among those in the nonsurgery group. Although it was suggested previously that this loss to follow-up would imply survival bias (14), survival bias will occur only if loss to follow-up resulting from dying of ovarian cancer changes the risk of breast cancer in the remaining study group. There are two reasons to think that this indeed is the case. First, compared with other BRCA1 mutations, the central region of the BRCA1 gene has been associated with a higher risk of ovarian cancer and a lower risk of breast cancer (18). If women with mutations in the central regions—suggested by the presence of ovarian cancer in their family—opt for a salpingo-oophorectomy more often than women with mutations in other parts of the gene, their intrinsic risk of breast cancer would be lower than the risk of the comparison group of carriers with mutations throughout the BRCA1 gene, which would result in an overestimation of the breast cancer risk reduction. This bias by indication may be increased by differential loss to follow-up. Women with mutations in the central region of the gene who have not opted for prophylactic surgery may develop ovarian cancer and die from this disease more often than women with other mutations. Thus, the appropriate subgroup in the comparison group may contribute fewer person-years at risk during follow-up. This increase in confounding by indication during follow-up is, in fact, survival bias. If bias by indication is properly taken into account, this potential survival bias will be avoided. Second, what may apply to confounding by indication may also apply to confounding in general, especially when one genetic mutation is associated with increased risks of two diseases that also share other risk factors. If confounding is not controlled for, dying from ovarian cancer may change the background breast cancer risk of the remaining comparison group. If a clinically undetected tumor is found in tissue removed during prophylactic surgery, the surgery did not prevent tumor occurrence, although it may increase life expectancy. How this possible favorable effect of surgery should be incorporated in the analysis is debatable. On the one hand, the woman cannot attribute person-years as a cancer-free person. On the other hand, had she not opted for surgery, the tumor might not have been diagnosed during follow-up. By counting the event in the surgery group, cancer risk is overestimated and efficacy is underestimated. By excluding the event, efficacy may be overestimated. Thus, for a conservative estimate of the efficacy of the intended prophylactic surgery, the cancer should be counted as an event in the surgery group, as in Rebbeck et al. (12). In addition, it is clinically important to estimate the efficacy of prophylactic surgery after exclusion of the women diagnosed at surgery. Such exclusion might generate a more realistic estimate of efficacy for women who undergo prophylactic surgery and prove to be cancer-free. The final evaluation of the efficacy of prophylactic surgery should be based on survival studies, in which women diagnosed at surgery should clearly be included in the surgery group. To guarantee that the baseline cancer risk of the surgery and nonsurgery groups are similar, the selection of the comparison group (BRCA1/2 carrier, free of cancer, and no prophylactic surgery) should not depend on cancer occurrence. A clear definition of the starting point of follow-up, at which time the subject should be free of cancer, is essential in this context. Before BRCA mutation testing became available in Western countries in 1995, the efficacy of prophylactic surgery was usually investigated in women selected from families with a high incidence of breast and/or ovarian cancers. Within these families, there is the possibility of ascertainment bias (23), which implies an overestimation of cancer risk because cancer events are included in the analysis that occurred before the date the first family member started to be screened or counseled (i.e., the date of ascertainment). For example, cancer risk would be overestimated if women 1, 3, and 4 (Fig. 1) were included in the analyses. Ascertainment biases could be controlled for by starting follow-up from the date woman 8 decided to be screened, the date of ascertainment for this family, or later (see Fig. 1). If follow-up for the nonsurgery group starts at the date of ascertainment, then for the surgery group, the person-years between the dates of ascertainment and surgery—which are cancer-free by definition—should not be excluded, as first depicted by Gail et al. (24). If follow-up starts at date of prophylactic surgery, these cancer-free person-years might be added to the person-years of the nonsurgery group. For example, Struewing et al. (25) investigated the occurrence of primary serous carcinoma of the peritoneum after prophylactic oophorectomy in a group of 12 families with multiple ovarian cancer cases. All women diagnosed with breast and/or ovarian cancer before the date of ascertainment for the family were correctly excluded, and the cancer-free first-degree family members of the excluded cases were selected into the study. Thus, ascertainment bias was avoided, but it is not clear whether the cancer-free person-years of the surgery group were allocated to the nonsurgery group. That allocation would reduce the cancer risk in the nonsurgery group and subsequently prevent an overestimation of the reduction of cancer risk after preventive surgery. In the study of Meijers-Heijboer et al. (11) person-years were correctly allocated. In recent publications (11–13), only women with a proven BRCA1 or BRCA2 mutation were selected for risk reduction analyses to obtain a homogeneous group regarding underlying cancer risk. The addition of this eligibility criterion may lead to testing bias, especially in retrospective cohort studies. Most women without cancer would generally not consider prophylactic surgery unless they are certain about their BRCA mutation carrier status (Fig. 1, woman 7). Thus, help with the decision-making process regarding prophylactic surgery is often the reason women without cancer seek genetic testing. Consequently, the date of testing generally precedes the date of the prophylactic surgery. However, testing behavior in women who do not seek prophylactic surgery is more complicated. Some women who do not undergo prophylactic surgery may be identified as mutation carriers only because of their cancer diagnosis (Fig. 1, women 4 and 6). Many women who do not consider prophylactic surgery and remain cancer-free may not undergo genetic testing at all (Fig. 1, woman 5) and are, therefore, not selected for study. This differential selection of identified mutation carriers with cancer from the total group of mutation carriers may lead to an overestimation of cancer incidence in the nonsurgery group if the cancer event is included in the analysis. Because of this cancer-induced testing bias, cancer risk reduction might be overestimated. To evaluate the possible differential selection of the nonsurgery group that might result in cancer-induced testing bias, the mean age of testing for those who develop cancer during follow-up and that for an age-matched sample that remains cancer free, might be compared. It is also informative to know the chronologic order of the dates of testing and cancer occurrence within the nonsurgery group, as illustrated in the study by Meijers-Heijboer et al. (11). In this study, women were included who visited the Family Cancer Clinic for breast cancer screening between 1992 and 2000. BRCA mutation testing was possible beginning in 1994, and only two of 76 (2.6%) women who underwent a prophylactic bilateral mastectomy a diagnosis after surgery, after the of follow-up. For the women in the nonsurgery group who no of women tested during follow-up was However, among the women who breast cancer in the nonsurgery group, four women were tested after their cancer This high that breast cancer is among the tested mutation carriers in the group, which might result in a cancer-induced testing bias, an overestimation of the risk reduction. of a in which cancer-induced testing bias could occur is found in the retrospective cohort study of Rebbeck et al. in which they ovarian and breast cancer risk after prophylactic oophorectomy in BRCA1/2 mutation carriers. of the nonsurgery group started at the date of the prophylactic date at which they were cancer-free. of the women in the surgery group were tested more than after the prophylactic surgery. In one the date of genetic testing was used as the of follow-up of the date of the prophylactic surgery. The was However, it is not clear which date of testing was used for the nonsurgery group in this the date of testing of their subject or their date of testing. In the an indeed of cancer-induced testing bias. Thus, cancer-induced testing bias could be by starting follow-up from the date of individual test or later, as by et al. The by women with an increased risk for breast and/or ovarian cancer to choose prophylactic surgery is often influenced by family such as a recently diagnosed cancer or a in a family member woman in Fig. 1). it may not be to follow-up at the date of testing to bias, if members of the same family are selected into both the surgery and nonsurgery women and 7 from the hypothetical family in Fig. had decided to undergo DNA testing with woman 8 (Fig. The women were found to be BRCA1/2 mutation carriers their mother for the time they continued with breast cancer screening. When woman was diagnosed with breast cancer, woman 7 about screening and opted for a prophylactic bilateral woman 5 continued breast cancer screening. Women 5 and might be as age-matched for woman but if follow-up starts at the individual date of testing, the breast cancer diagnosed in woman was the reason for the prophylactic surgery in woman would be counted as an event in the analysis. this would result in an overestimation of the breast cancer risk among women in the nonsurgery group in an overestimation of the breast cancer risk reduction after prophylactic bilateral mastectomy. Thus, if members of the same family are selected into the study the date of prophylactic surgery of the surgery subject should be considered in the as illustrated by Hartmann et al. (22). cases of breast cancer were in a group of high-risk women who had prophylactic bilateral mastectomy. The of breast among women without prophylactic bilateral mastectomy was from a group of sisters without bilateral from age to the of follow-up and for However, if the of follow-up of the group was included from the date of the prophylactic bilateral the of breast would be which is The reduction of breast cancer risk in these two did not differ possibly because the of breast among women in the prophylactic bilateral mastectomy group was bias may not be to studies that are family-based by such as the study of Hartmann et al. mentioned The matching factors used in other efficacy studies (i.e., mutation, may the selection of relatives into the nonsurgery group. This selection may increase bias. To familial-event bias, the for of follow-up is the age at which the was tested or the age of the at the date of her prophylactic surgery (i.e., her age at Fig. Because women in the comparison group should be cancer-free at this in our example, woman should be excluded as a and woman 5 would remain an with her age at as the starting point of follow-up. women from the breast cancer risk is reduced by about after a salpingo-oophorectomy An important when evaluating breast cancer risk reduction after prophylactic bilateral mastectomy is the possibility that women for this prophylactic surgery are more likely to also for prophylactic salpingo-oophorectomy. prophylactic salpingo-oophorectomy is a in studies the efficacy of prophylactic bilateral mastectomy and might the In one study prophylactic salpingo-oophorectomy was included as a in a (11). However, if the of women in the prophylactic bilateral mastectomy group also for a prophylactic salpingo-oophorectomy, this may and an analysis to women who underwent both prophylactic might be a salpingo-oophorectomy may not be an effect The to for testing or prophylactic surgery may be related to risk factors for breast and/or ovarian cancer. Meijers-Heijboer et al. suggested that women may be more to for prophylactic surgery than Because is an that breast and ovarian cancer risk, this if not for, would result in an overestimation of the efficacy of prophylactic surgery. known risk factors have been considered in efficacy studies, with one (14) (see Cancer After Bias of section). It is clear that should for in analyses of the efficacy of prophylactic however, the for changes in risk factors that are of prophylactic surgery, such as of or after a salpingo-oophorectomy, is The of the surgery and of such risk factors might be considered in the analyses. For example, if of breast cancer risk in BRCA1/2 mutation carriers, as it for the then it might be informative to estimate the efficacy of a prophylactic salpingo-oophorectomy or not by Several forms of bias can occur in studies the efficacy of prophylactic surgery in women at high risk for breast and/or ovarian cancer. First, confounding by indication may lead to an underestimation of the risk reduction after prophylactic for example, the of ovarian cancer in a family may be associated with the to for a prophylactic salpingo-oophorectomy, ovarian cancer may be prevalent in the family of nonsurgery subjects. Second, cancer-induced testing bias may occur when studies are to known BRCA1/2 mutation carriers. For example, women not prophylactic surgery may be identified as mutation carriers only because they develop breast and/or ovarian cancer at some women who do not consider prophylactic surgery and remain cancer-free may not undergo genetic testing and are not selected for the study. familial-event bias may arise when the to for prophylactic surgery is influenced by a recent cancer diagnosis in a while this relative also is selected into the nonsurgery group. the cancer-induced testing bias and the familial-event bias may lead to an overestimation of risk reduction by prophylactic surgery. To date, these potential biases have in efficacy studies. An study for the efficacy of prophylactic surgery is a follow-up study, but for a follow-up study on a cohort that is identified and those who is an A cohort of BRCA1/2 carriers that are free of the tumor study at the of follow-up. It may not be to a as as are properly considered in the analysis. effect are the genetic mutation and a salpingo-oophorectomy when evaluating the efficacy of a prophylactic mastectomy. are and other known risk factors of the tumor study. The risk factors of breast and ovarian cancer should be of the surgery group starts at the age of prophylactic surgery or at the age of the genetic test of the nonsurgery subjects also starts at the age of the genetic test However, if a relative of the is included in the surgery group, the age of the at the time of the prophylactic surgery is used as the of follow-up, if this age is greater than the age at testing. If consider the evaluation of prophylactic surgery to be essential for of women at high-risk for breast and/or ovarian cancer, should consider the potential biases because biases result in an overestimation of the from prophylactic surgery. It however, not be possible to all of the methodologic problems of efficacy studies, or would be only at the of a loss of In such and for studies a more about potential including an of their and is in this can BRCA1/2 mutation carriers, clinical and obtain more about the extent of cancer risk reduction from prophylactic surgery. This valid estimate of risk reduction may more crucial in the future when available regarding the efficacy of such as and such as of prophylactic surgery in women with a high risk of breast and/or ovarian of of prophylactic surgery in women with a high risk of breast and/or ovarian of family and time of family members being tested for BRCA1/2 mutations. to family living living with diagnosed breast or ovarian with living with BRCA1/2 no BRCA1/2 age at breast cancer age at ovarian cancer date of date of and date of genetic testing for BRCA1/2 mutation status date of prophylactic surgery. of of follow-up in a woman with prophylactic surgery (woman and her potential sisters 5 and 6). age at of age at test result for BRCA1/2 age at prophylactic age at the date of the prophylactic surgery of the age at breast cancer follow-up from age at follow-up from age at test follow-up from age at surgery, or age at test breast cancer.
No takes yet. Share an insight, caveat, or question.
Klaren et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: